Log in to search using one of your social media accounts:

 

Neoadjuvant Goserelin for Triple Negative Breast Cancer
Condition:   Breast Cancer Triple Negative Intervention:   Drug: Goserelin Sponsor:   Kasr El Aini Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2018 Category: Research Source Type: clinical trials

Preoperative Localization of Sentinel Lymph Node in Breast Cancer Patients By Novel Computed Tomography-Lymphography Guided Technique
Condition:   Breast Cancer Intervention:   Device: preoperative localization of SLN detected by CTLG by either methods Sponsor:   Mansoura University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2018 Category: Research Source Type: clinical trials

Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer
Condition:   Metastatic Breast Cancer Intervention:   Diagnostic Test: FES PET/CT Sponsor:   Institut Cancerologie de l'Ouest Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2018 Category: Research Source Type: clinical trials

Facilitating Oncology Patient-Clinician Communication Via E-health Innovations
Condition:   Breast Cancer Intervention:   Behavioral: CaringGuidance™ After Breast Cancer Diagnosis Sponsor:   University of Nebraska Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2018 Category: Research Source Type: clinical trials

Preoperative Localization of Sentinel Lymph Node in Breast Cancer Patients By Novel Computed Tomography-Lymphography Guided Technique
Condition:   Breast Cancer Intervention:   Device: preoperative localization of SLN detected by CTLG by either methods Sponsor:   Mansoura University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2018 Category: Research Source Type: clinical trials

Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer
Condition:   Metastatic Breast Cancer Intervention:   Diagnostic Test: FES PET/CT Sponsor:   Institut Cancerologie de l'Ouest Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2018 Category: Research Source Type: clinical trials

Facilitating Oncology Patient-Clinician Communication Via E-health Innovations
Condition:   Breast Cancer Intervention:   Behavioral: CaringGuidance™ After Breast Cancer Diagnosis Sponsor:   University of Nebraska Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2018 Category: Research Source Type: clinical trials

Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer
Condition:   Metastatic Breast Cancer Intervention:   Diagnostic Test: FES PET/CT Sponsor:   Institut Cancerologie de l'Ouest Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2018 Category: Research Source Type: clinical trials

Preoperative Localization of Sentinel Lymph Node in Breast Cancer Patients By Novel Computed Tomography-Lymphography Guided Technique
Condition:   Breast Cancer Intervention:   Device: preoperative localization of SLN detected by CTLG by either methods Sponsor:   Mansoura University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2018 Category: Research Source Type: clinical trials

A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants
Condition:   Locally Advanced or Metastatic Breast Cancer Intervention:   Drug: Eribulin mesylate Sponsor:   Eisai Korea Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 19, 2018 Category: Research Source Type: clinical trials

Identification of New Prognostic Markers for Breast Cancer.
Condition:   Breast Cancer Intervention:   Other: Conventional treatment protocols of breast cancer Sponsor:   University Hospital, Grenoble Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 16, 2018 Category: Research Source Type: clinical trials

Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer
Conditions:   Breast Neoplasms;   Early Detection of Cancer Interventions:   Behavioral: Patient activation;   Behavioral: Primary care physician activation;   Behavioral: Control Sponsors:   Duke University;   National Cancer Institute (NCI);   St. Jude Children's Research Hospital;   Memorial Sloan Kettering Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 16, 2018 Category: Research Source Type: clinical trials

Identification of New Prognostic Markers for Breast Cancer.
Condition:   Breast Cancer Intervention:   Other: Conventional treatment protocols of breast cancer Sponsor:   University Hospital, Grenoble Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 16, 2018 Category: Research Source Type: clinical trials

Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer
Conditions:   Breast Neoplasms;   Early Detection of Cancer Interventions:   Behavioral: Patient activation;   Behavioral: Primary care physician activation;   Behavioral: Control Sponsors:   Duke University;   National Cancer Institute (NCI);   St. Jude Children's Research Hospital;   Memorial Sloan Kettering Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 16, 2018 Category: Research Source Type: clinical trials

Identification of New Prognostic Markers for Breast Cancer.
Condition:   Breast Cancer Intervention:   Other: Conventional treatment protocols of breast cancer Sponsor:   University Hospital, Grenoble Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 16, 2018 Category: Research Source Type: clinical trials

Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer
Conditions:   Breast Neoplasms;   Early Detection of Cancer Interventions:   Behavioral: Patient activation;   Behavioral: Primary care physician activation;   Behavioral: Control Sponsors:   Duke University;   National Cancer Institute (NCI);   St. Jude Children's Research Hospital;   Memorial Sloan Kettering Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 16, 2018 Category: Research Source Type: clinical trials

Identification of New Prognostic Markers for Breast Cancer.
Condition:   Breast Cancer Intervention:   Other: Conventional treatment protocols of breast cancer Sponsor:   University Hospital, Grenoble Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 16, 2018 Category: Research Source Type: clinical trials

Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer
Conditions:   Breast Neoplasms;   Early Detection of Cancer Interventions:   Behavioral: Patient activation;   Behavioral: Primary care physician activation;   Behavioral: Control Sponsors:   Duke University;   National Cancer Institute (NCI);   St. Jude Children's Research Hospital;   Memorial Sloan Kettering Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 16, 2018 Category: Research Source Type: clinical trials

Identification of New Prognostic Markers for Breast Cancer.
Condition:   Breast Cancer Intervention:   Other: Conventional treatment protocols of breast cancer Sponsor:   University Hospital, Grenoble Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 16, 2018 Category: Research Source Type: clinical trials

Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer
Conditions:   Breast Neoplasms;   Early Detection of Cancer Interventions:   Behavioral: Patient activation;   Behavioral: Primary care physician activation;   Behavioral: Control Sponsors:   Duke University;   National Cancer Institute (NCI);   St. Jude Children's Research Hospital;   Memorial Sloan Kettering Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 16, 2018 Category: Research Source Type: clinical trials

Identification of New Prognostic Markers for Breast Cancer.
Condition:   Breast Cancer Intervention:   Other: Conventional treatment protocols of breast cancer Sponsor:   University Hospital, Grenoble Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 16, 2018 Category: Research Source Type: clinical trials

Optimized Rehabilitation Following Primary Breast Cancer Surgery
Conditions:   Rehabilitation;   Breast Neoplasms;   Psychological Distress Interventions:   Other: Individualised rehabilitation;   Other: Care as usual Sponsor:   Lund University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 15, 2018 Category: Research Source Type: clinical trials

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Conditions:   Breast Adenocarcinoma;   Recurrent Breast Carcinoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mycosis Fungoides;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Ref ractory Nodal Marginal Zone Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Stage IV Breast Cancer AJCC&nb...
Source: ClinicalTrials.gov - February 14, 2018 Category: Research Source Type: clinical trials

Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer
Condition:   Breast Cancer Interventions:   Drug: EG12014;   Drug: Herceptin Sponsor:   EirGenix, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2018 Category: Research Source Type: clinical trials

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Conditions:   Breast Adenocarcinoma;   Recurrent Breast Carcinoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mycosis Fungoides;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Ref ractory Nodal Marginal Zone Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Stage IV Breast Cancer AJCC&nb...
Source: ClinicalTrials.gov - February 14, 2018 Category: Research Source Type: clinical trials

Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer
Condition:   Breast Cancer Interventions:   Drug: EG12014;   Drug: Herceptin Sponsor:   EirGenix, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2018 Category: Research Source Type: clinical trials

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Conditions:   Breast Adenocarcinoma;   Recurrent Breast Carcinoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mycosis Fungoides;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Ref ractory Nodal Marginal Zone Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Stage IV Breast Cancer AJCC&nb...
Source: ClinicalTrials.gov - February 14, 2018 Category: Research Source Type: clinical trials

Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer
Condition:   Breast Cancer Interventions:   Drug: EG12014;   Drug: Herceptin Sponsor:   EirGenix, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2018 Category: Research Source Type: clinical trials

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Conditions:   Breast Adenocarcinoma;   Recurrent Breast Carcinoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mycosis Fungoides;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Ref ractory Nodal Marginal Zone Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Stage IV Breast Cancer AJCC&nb...
Source: ClinicalTrials.gov - February 14, 2018 Category: Research Source Type: clinical trials